Share This Page
Bulk Pharmaceutical API Sources for DILTZAC
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for DILTZAC
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| ChemExper Chemical Directory | ⤷ Start Trial | jk PR@NCMelpAFRJJJIQQKII[SHq\mKtZtEPATALMUTBDSH@ | ⤷ Start Trial |
| NovoSeek | ⤷ Start Trial | 39186 | ⤷ Start Trial |
| MolPort | ⤷ Start Trial | MolPort-002-509-369 | ⤷ Start Trial |
| Hangzhou APIChem Technology | ⤷ Start Trial | AC-936 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk Active Pharmaceutical Ingredient (API) Sources for Diltzac
Introduction
Diltzac, a proprietary pharmaceutical product containing diltiazem, is widely used to manage cardiovascular conditions such as hypertension, angina pectoris, and certain arrhythmias. Its efficacy hinges on the consistent quality of its active pharmaceutical ingredient (API), diltiazem hydrochloride, which is synthesized and supplied by various bulk API manufacturers globally. This article provides a detailed overview of key API sources for diltiazem, evaluating their market presence, regulatory compliance, and strategic considerations for pharmaceutical companies sourcing this critical ingredient.
Diltiazem Hydrochloride: Overview
Diltiazem hydrochloride, chemically known as 2-(2-dimethylaminoethyl)-5-(4-methoxyphenyl)-3-oxo-6-chromenylacetamide hydrochloride, acts as a calcium channel blocker. It is classified as an existing, well-established API with generic manufacturing widespread among reputable suppliers. Ensuring high purity, consistent bioavailability, and regulatory compliance are essential criteria for sourcing diltiazem API.
Major API Manufacturers for Diltiazem Hydrochloride
1. North American and European API Suppliers
a. Hikma Pharmaceuticals (Middle East, US, Europe)
Hikma supplies pharmaceutical-grade APIs, including diltiazem hydrochloride, globally. The company maintains high manufacturing standards compliant with current Good Manufacturing Practices (cGMP), with facilities approved by the FDA and EMA. Their strategic positioning ensures reliable supply chains for North American and European markets.
b. Teva Pharmaceutical Industries (Israel)
As one of the world's largest generic API producers, Teva’s portfolio includes diltiazem hydrochloride. Their manufacturing facilities adhere to cGMP standards, with consistent batch-to-batch quality and robust regulatory compliance frameworks.
c. Aurobindo Pharma (India)
Aurobindo has established a significant presence in the API space, supplying diltiazem hydrochloride globally. Their facilities in India are certified by agencies like the US FDA, EMA, and TGA, ensuring high quality and regulatory acceptance.
d. Sun Pharma (India)
Sun Pharma offers a wide range of APIs, including diltiazem hydrochloride, with manufacturing units compliant with international standards. Their focus on quality control ensures their API conforms to pharmacopoeial specifications [1].
2. Asian API Suppliers
a. Zhejiang Hisun Pharmaceutical (China)
This Chinese manufacturer supplies bulk diltiazem hydrochloride, with APIs adhering to pharmacopoeial standards and ISO certifications. Their aggressive pricing and large-scale production capacity make them appealing for cost-sensitive markets.
b. Hubei Millennium Medicine (China)
Millennium also produces diltiazem hydrochloride API, emphasizing quality control and compliance with GMP guidelines. Their export markets include Latin America, Southeast Asia, and parts of Africa [2].
c. Wockhardt (India)
With facilities certified by regulatory authorities, Wockhardt supplies high-quality APIs, including diltiazem hydrochloride, with an emphasis on cGMP compliance.
3. Emerging and Specialized API Suppliers
a. Pharmaceutica (Argentina)
An emerging supplier with an increasing presence in Latin America, Pharmaceutica offers diltiazem API verifying pharmacopoeial standards.
b. Cipla (India)
Cipla’s global API manufacturing, including diltiazem, emphasizes quality and affordability, with cGMP-compliant facilities certified by multiple global agencies.
c. Synthesis and Contract Manufacturing Organizations (CMOs)
Several CMOs in India, China, and Eastern Europe offer custom synthesis of diltiazem, often catering to pharmaceutical companies seeking flexibility and supply chain diversification.
Key Considerations for Sourcing Diltiazem API
Regulatory Compliance and Quality Assurance
Sourcing from manufacturers with comprehensive regulatory approvals (FDA, EMA, PMDA) is crucial. This reduces the risk of regulatory delays and batch rejections. Suppliers with strong GMP compliance and ISO certifications typically provide APIs with consistent purity (>99%) and suitable impurity profiles.
Manufacturing Capacity and Supply Stability
For manufacturing scale-up or continuous supply, vendors with reliable capacity and a robust supply chain are preferred. Market stability may require diversifying sources, especially given geopolitical dynamics affecting Chinese and Indian API supplies.
Cost and Lead Time
While India and China dominate as cost-effective API providers, bringing in API from high-regulation markets like Europe and North America often incurs higher costs but offers advantages in regulatory ease and quality assurance.
Intellectual Property and Confidentiality
Ensuring procurement agreements protect proprietary formulations and manufacturing processes is vital, especially with custom synthesis options. Confidentiality clauses and patent considerations should be negotiated with suppliers.
Market Trends and Future Outlook
The API sourcing landscape for diltiazem hydrochloride reflects broader trends in pharmaceutical manufacturing — globalization, increasing regulatory scrutiny, and emphasis on quality assurance. Contract manufacturing and strategic alliances enable pharmaceutical companies to diversify risk, optimize costs, and meet demand fluctuations.
The ongoing regulatory tightening, particularly concerning impurities and residual solvents, necessitates robust quality management systems. Additionally, supply chain disruptions, as seen during the COVID-19 pandemic, highlight the importance of diversified sourcing.
Furthermore, the push toward sustainable manufacturing practices and environmental compliance may influence future API suppliers’ operational standards, impacting sourcing decisions.
Strategic Sourcing Recommendations
- Prioritize suppliers with proven regulatory track records and cGMP certifications.
- Establish multi-source agreements to mitigate supply chain risks.
- Conduct rigorous supplier audits and site inspections.
- Monitor global regulatory updates affecting API quality standards.
- Engage with suppliers capable of providing consistent documentation and stability data.
Key Takeaways
- The primary global API sources for diltiazem hydrochloride include manufacturers in India, China, Israel, and the Middle East, with established reputations for quality and compliance.
- Regulatory approvals (FDA, EMA, TGA) significantly influence supplier credibility and market acceptance.
- Diversification of suppliers mitigates risks associated with geopolitical, logistical, and regulatory challenges.
- Cost remains a major but balanced consideration against quality and supply reliability.
- Ongoing regulatory developments and sustainability trends will continue to shape API sourcing strategies for diltiazem.
FAQs
Q1: What are the top regulatory considerations when sourcing diltiazem API?
A1: Ensuring supplier compliance with cGMP standards, obtaining appropriate regulatory approvals (FDA, EMA), and verifying impurity profiles align with pharmacopoeial standards are critical.
Q2: Which countries dominate the production of diltiazem hydrochloride API?
A2: India and China are the leading producers, offering cost-effective options with extensive manufacturing capacities. Suppliers from Israel and the Middle East also play notable roles.
Q3: How can pharmaceutical companies mitigate supply chain risks for diltiazem API?
A3: By establishing multi-source agreements, conducting regular supplier audits, and maintaining strategic stockpiles.
Q4: Are there significant quality differences among API suppliers from different regions?
A4: Yes. While many suppliers from India and China meet high standards, variances in quality control, documentation, and regulatory compliance can exist. Due diligence is essential.
Q5: What future trends could influence API sourcing strategies for diltiazem?
A5: Increased regulatory stringency, sustainability initiatives, and technological advancements in manufacturing processes will likely impact sourcing, emphasizing quality, transparency, and supply resilience.
References
[1] U.S. Food and Drug Administration (FDA). “Approved Drug Products with Therapeutic Equivalence Evaluations,” 2022.
[2] Hubei Millennium Medicine. Company website and certification documentation.
More… ↓
